Insulet is trading 23% down at $131.65 after its second-quarter earnings release showed strong revenue and EPS beats but a cut to full-year 2026 sales guidance.
- The company reduced its constant-currency revenue growth outlook and lowered U.S. Omnipod growth targets as it recalibrates its Type 2 diabetes rollout.
- Investors appear to be punishing the stock for the long-term guidance cut despite robust international Omnipod growth and better-than-expected Q2 results.